Research Articles

Effect of dose increase or cimetidine co-administration on albendazole bioavailability

The low bioavailability of albendazole affects the therapeutic response in patients with echinococcosis. Cimetidine co-administration is reported to improve bioavailability. To analyze the assumed dose-dependent bioavailability of albendazole, we administered 5 to 30 mg/kg albendazole to 6 male volunteers in a randomized cross-over study. To assess the effect of cimetidine (10 mg/kg twice daily), the drug was given with albendazole (20 mg/kg). A dose-dependent bioavailability was not observed. This was due to inter-individual variability of the maximal concentration (Cmax 38%-72%) of albendazole sulphoxide (ABZSX), the active metabolite of albendazole. Cmax was 0.21+/-0.14 mg/L after 5 mg/kg and 0.39+/-0.19 mg/L after 30 mg/kg albendazole (P = 0.217). Cimetidine tended to decrease Cmax by 52% (P = 0.109) and significantly inhibited ABZSX breakdown as indicated by the prolongation of ABZSX elimination half-life from 7.4+/-3.3 hr to 19.0+/-11.7 hr (P = 0.028). Remarkably, the inter-individual variability of Cmax was significantly lower during cimetidine co-administration: 14% versus 72%.

This article has been cited by other articles:

				H. G. Schipper, S. Simsek, M. A. van Agtmael, and K. P. van Lienden Bone Hydatid Disease Refractory to Nitazoxanide Treatment Am J Trop Med Hyg, September 1, 2009; 81(3): 446 - 448. [Abstract] [Full Text] [PDF]

				I. M. Rigter, H. G. Schipper, R. P. Koopmans, H. J. M. van Kan, H. W. Frijlink, P. A. Kager, and H.-J. Guchelaar Relative Bioavailability of Three Newly Developed Albendazole Formulations: a Randomized Crossover Study with Healthy Volunteers Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1051 - 1054. [Abstract] [Full Text] [PDF]